Skip to main content

Connective Tissue Diseases

4
Pipeline Programs
5
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
150%
Monoclonal Antibody
150%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
1
1
SirolimusPhase 41 trial
TelitaciceptPhase 21 trial
Active Trials
NCT05998759Recruiting296Est. Dec 2025
NCT03688191Unknown20Est. Sep 2019
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
BelimumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06716606Recruiting514Est. Dec 2029
Autonomous Therapeutics
1 program
1
TelitaciceptPhase 2
Biocorp
BiocorpFrance - Issoire
1 program
CAR-TN/ACell Therapy1 trial
Active Trials
NCT07152223Withdrawn0Est. Mar 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Pulmonary function testN/A1 trial
Active Trials
NCT04095351Recruiting120Est. Oct 2034

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UNION therapeuticsSirolimus
ViiV HealthcareBelimumab
UNION therapeuticsTelitacicept
BiocorpCAR-T
Boehringer IngelheimPulmonary function test

Clinical Trials (5)

Total enrollment: 950 patients across 5 trials

NCT03688191UNION therapeuticsSirolimus

Study of Sirolimus in CTD-TP in China

Start: Sep 2017Est. completion: Sep 201920 patients
Phase 4Unknown
NCT06716606ViiV HealthcareBelimumab

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

Start: Dec 2024Est. completion: Dec 2029514 patients
Phase 3Recruiting
NCT05998759UNION therapeuticsTelitacicept

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Start: Dec 2023Est. completion: Dec 2025296 patients
Phase 2Recruiting
NCT07152223BiocorpCAR-T

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Start: Aug 2025Est. completion: Mar 20260
N/AWithdrawn
NCT04095351Boehringer IngelheimPulmonary function test

Connective Tissue Diseases and Lung Manifestations

Start: Dec 2019Est. completion: Oct 2034120 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 950 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.